Toward an HIV Type 1 Vaccine that Generates Potent, Broadly Cross-Reactive Neutralizing Antibodies
- 20 May 1999
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 15 (8) , 689-698
- https://doi.org/10.1089/088922299310773
Abstract
No abstract availableKeywords
This publication has 119 references indexed in Scilit:
- Neutralization Escape in Human Immunodeficiency Virus Type 1–Infected Long‐Term NonprogressorsThe Journal of Infectious Diseases, 1999
- Fusion-Competent Vaccines: Broad Neutralization of Primary Isolates of HIVScience, 1999
- Analysis of the Interaction of Antibodies with a Conserved, Enzymatically Deglycosylated Core of the HIV Type 1 Envelope Glycoprotein 120AIDS Research and Human Retroviruses, 1998
- Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.Proceedings of the National Academy of Sciences, 1994
- Structural Rearrangements in the Transmembrane Glycoprotein after Receptor BindingImmunological Reviews, 1994
- A Synthetic Peptide from HIV-1 gp41 Is a Potent Inhibitor of Virus-Mediated Cell—Cell FusionAIDS Research and Human Retroviruses, 1993
- Studies on the Specificity of the Vaccine Effect Elicited by Inactivated Simian Immunodeficiency VirusAIDS Research and Human Retroviruses, 1993
- Detection of Anti-Human Cell Antibodies in Sera from Macaques Immunized with Whole Inactivated VirusAIDS Research and Human Retroviruses, 1992
- A Caution on the Use of SIV/HIVgagAntigen Detection Systems in Neutralization AssaysAIDS Research and Human Retroviruses, 1992
- AIDS responseNature, 1991